Harnessing the cell death pathway for targeted cancer treatment

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Genotoxic cancer therapies primarily target apoptosis, a programmed cell death pathway.
• Cancer cells often develop resistance to apoptosis due to cellular defects, reducing treatment efficacy.
• Investigating alternative cell death mechanisms is crucial for overcoming therapeutic resistance.

Purpose of the Study:

• To review apoptosis, autophagy, and necrosis in cancer development and drug resistance.
• To provide an updated preclinical and clinical overview of inhibitors targeting these distinct cell death pathways.
• To identify molecular targets for enhancing current cancer therapy efficacy and specificity.

Main Methods:

• Literature review of apoptosis, autophagy, and necrosis.
• Analysis of tumorigenesis and drug resistance mechanisms.
• Review of preclinical and clinical studies on cell death pathway inhibitors.

Main Results:

• Apoptosis resistance is a significant challenge in cancer treatment.
• Autophagy and necrosis represent promising alternative therapeutic targets.
• Inhibitors targeting these pathways show potential in preclinical and clinical settings.

Conclusions:

• Targeting distinct cell death pathways beyond apoptosis is a viable strategy for cancer therapy.
• Further research into autophagy and necrosis inhibitors can enhance current cancer treatments.
• Identifying specific molecular targets will improve the efficacy and specificity of cancer interventions.